Atlas Trials

Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients

Clinical trial NCT06009627 · COMPLETED

Trial details

NCT number
NCT06009627
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Status
COMPLETED
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Breast Cancer
Start date
2023-04-11
Primary completion
2025-03-11
Enrollment
119

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.